天津医药

天津医药 ›› 2021, Vol. 49 ›› Issue (10): 1072-1077.doi: 10.11958/20210645

• 临床研究 • 上一篇    下一篇

基因重组人卵泡刺激素用于非低反应人群卵泡期长效促排卵方案的疗效分析

潘莉娜，黄官友，黄永俐，许文芳，胡竹，赵淑云，陈卓   

  1. 贵州医科大学附属医院生殖医学中心（邮编550004）
  • 收稿日期:2021-03-19 修回日期:2021-06-23 出版日期:2021-10-15 发布日期:2021-10-15
  • 通讯作者: 陈卓 E-mail:hf3457214@163.com
  • 基金资助:
    贵州省科技计划项目

Efficacy analysis of recombinant human follicle stimulating hormone for long-term treatment of follicular phase in non-low response population

PAN Li-na, HUANG Guan-you, HUANG Yong-li, XU Wen-fang, HU Zhu, ZHAO Shu-yun, CHEN Zhuo #br#   

  1. Center for Reproductive Medicine, the Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China
  • Received:2021-03-19 Revised:2021-06-23 Published:2021-10-15 Online:2021-10-15

PDF (PC)

2802

摘要： 目的 比较2种基因重组人卵泡刺激素（rFSH）制剂用于卵泡期长效促排卵方案的非低反应人群的疗效及 安全性。方法 回顾性纳入首次行卵泡期长效促排卵方案体外受精/胞质内单精子显微注射技术（IVF/ICSI）助孕治 疗的非卵巢低反应不孕患者，均行控制性卵巢刺激（COS）卵泡期长效促排卵方案治疗，根据使用rFSH不同分为国产 rFSH组（267个周期）和进口rFSH组（240个周期）。比较2组患者在超促排卵过程中的卵巢反应、用药情况、卵子受 精及胚胎情况、新鲜胚胎移植及胚胎解冻移植后的妊娠率及活产率。结果 超促排卵过程中，国产rFSH组HCG注 射日雌二醇（E2）水平低于进口rFSH组（P＜0.05），2组Gn总量、Gn使用天数、减数分裂中Ⅱ期（MⅡ）卵数、D3优质胚 胎数、获得优质囊胚数等差异均无统计学意义（P＞0.05）。主要疗效指标中，国产rFSH组及进口rFSH组的平均获卵 数、新鲜胚胎移植周期临床妊娠率、冻融移植周期临床妊娠率等差异均无统计学意义（P＞0.05），且2组患者的一次 COS累积活产率比较差异均无统计学意义（P＞0.05）。结论 非低反应患者在卵泡期长效促排卵方案中使用国产 rFSH或进口rFSH可获得同等安全的促排卵疗效和妊娠结局。

关键词: 卵泡刺激素, 人, 体外受精, 胚胎移植, 非低反应人群, 卵泡期长效促排卵方案, 临床妊娠率, 活产率

Abstract: Objective To compare the efficacy and safety of domestic and imported recombinant human follicle stimulating hormone (rFSH) preparation for ovulation induction in non-low-response population with long-acting program in follicular phase. Methods Non-ovarian infertility patients with low response were retrospectively enrolled in our center for the first time to receive long-acting follicular phase IVF/ICSI assisted fertility treatment, all of whom received a COS longacting follicular phase therapy, and were divided into the domestic rFSH group (n=267) and the imported rFSH group (n= 240) according to different use of rFSH. Ovarian response, medication, egg fertilization and embryo, fresh embryo transfer and embryo thawing transfer were compared between the two groups. Results During the process of superovulation, the level of E 2 on HCG day was lower in the domestic rFSH group than that in the imported rFSH group (P＜0.05). There were no significant differences in total Gn, days of Gn use, the number of MⅡ eggs, the number of D3 excellent embryos and number of high-quality blastocysts between the two groups (P＞0.05). In the primary efficacy indicators, there were no significant differences in the average number of egg retrieved, cumulative live birth rate of one COS number of fresh embryos, the clinical pregnancy rate in the transplantation cycle, and the clinical pregnancy rate in the freeze-thaw transplantation cycle between the two groups (P＞0.05). Conclusion Compared with imported rFSH in the follicular phase, domestic rFSH can achieve the same safe efficacy and clinical outcome in non-low response patients.

Key words: follicle stimulating hormone, human, fertilization in vitro, embryo transfer, non-low response population, long-acting program for follicular phase, clinical pregnancy rate, live birth rate